Buscar
-
Post-exposure prophylaxis following high-risk contact with Ebola virus, using immunotherapies with monoclonal antibodies, in the eastern Democratic Republic of the Congo: an emergency use program
(International Journal of Infectious Diseases. vol. 113, pp. 166-167, 2021-09-26)Article de revueLibre acceso -
Immune evasion means we need a new COVID-19 social contract
(The Lancet Public Health. vol. 6, n° 4, pp. e199-e200, 2021-02)Article de revueLibre acceso -
Clinical presentation, outcomes and factors associated with mortality: A prospective study from three COVID-19 referral care centres in West Africa
(International Journal of Infectious Diseases. vol. 108, pp. 45-52, 2021-07)Article de revueLibre acceso -
Combined treatment of molnupiravir and favipiravir against SARS-CoV-2 infection: One + zero equals two?
(EBioMedicine. vol. 74, 2021-11-09)Article de revueLibre acceso -
Travel-related infections presenting in Europe: A 20-year analysis of EuroTravNet surveillance data
(The Lancet Regional Health - Europe. vol. 1, pp. 100001, 2021-02)Article de revueLibre acceso -
Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2
(Antiviral Research. vol. 193, pp. 105137, 2021-07-12)Article de revueLibre acceso -
Maternal Infection and Adverse Pregnancy Outcomes among Pregnant Travellers: Results of the International Zika Virus in Pregnancy Registry
(Viruses. vol. 13, n° 2, 2021-02-22)Article de revueLibre acceso -
Depression and anxiety symptoms in young adults before and during the COVID-19 pandemic: evidence from a Canadian population-based cohort
(Annals of General Psychiatry. vol. 20, n° 1, pp. 42, 2021-09-08)Article de revueLibre acceso -
Direct, indirect and total effect of HIV coinfection on the risk of non-liver-related cancer in hepatitis C virus-infected patients treated by direct-acting antivirals: a mediation analysis
(HIV Medicine, 2021-08-17)Article de revueLibre acceso -
Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths
(Science Immunology. vol. 6, n° 62, 2021-08-19)Article de revueLibre acceso